Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?

摘要: The efficacy and toxicity of any given drug can vary substantially from one individual to another. heterogeneity in genetics contributes, part, this variability. Pharmacogenomics uses each patient’s genetic information identify the with best efficacy-safety profile for that patient. However, is also present individuals’ preferences alternate profiles. We argue as healthcare evolves towards individualised therapy, preference elicitation cost-effectiveness analysis should be performed at level maximise societal welfare.